Mari Haramoto

Title: Innovations of Mari Haramoto in Cancer Treatment

Introduction

Mari Haramoto is a prominent inventor based in Kyoto, Japan. She has made significant contributions to the field of cancer treatment through her innovative research and development of chimeric peptides. With a total of 3 patents, her work focuses on creating effective anticancer agents that target specific receptors on cancer cells.

Latest Patents

One of her latest patents is titled "Selective anticancer chimeric peptides which bind transferrin receptor." This invention aims to provide a substance usable as an anticancer agent or drug delivery system (DDS) that possesses intracellular stability and can evade side effects associated with normal cells. The novel chimeric peptide developed by Haramoto targets cancer cells that overexpress the epidermal growth factor receptor (EGFR) using a binding peptide sequence and a lytic peptide sequence. This innovative approach effectively addresses the challenges of traditional cancer treatments.

Another significant patent is "Selective anticancer chimeric peptides which bind neuropilin receptor." Similar to her previous work, this invention also focuses on creating a substance that can serve as an anticancer agent or DDS. The chimeric peptide targets cancer cells overexpressing EGFR, utilizing a binding peptide and a cytotoxic peptide to achieve its objectives. This advancement highlights Haramoto's commitment to developing targeted therapies for cancer treatment.

Career Highlights

Throughout her career, Mari Haramoto has worked with various organizations, including Stella Pharma Corporation. Her expertise in peptide technology and cancer research has positioned her as a leading figure in the field.

Collaborations

Haramoto has collaborated with notable colleagues such as Koji Kawakami and Masayuki Kohno. These partnerships have contributed to her innovative research and the successful development of her patented technologies.

Conclusion

Mari Haramoto's contributions to cancer treatment through her innovative chimeric peptides demonstrate her dedication to advancing medical science. Her work not only addresses critical challenges in cancer therapy but also paves the way for future innovations in targeted treatments.